SKB264 临床进展顺利，国内海外同步加速推进中：2L EGFRmt NSCLC 国内注册临床数据预计于25 年 ESMO 大会读出，目前国内注册临床包含肺癌3 个（联用K药治疗1L EGFRwt NSCLC PD-L1 TPS≥1%； 联用K 药针对1L EGFRwt nsq PDL1(-)NSCLC；联用奥希治疗 1L EGFRmt nsq NSCLC）和乳腺癌2 个 （1L TNBC；2L+ HR+/HER2- BC）；默沙东已开启14 个海外临床，全面覆盖了肺癌5 个（联合K 药新 辅助Ⅱ-Ⅲb NSCLC、联合K 药治疗1L PD-L1 高表达、单药治疗EGFR TKI耐药的2L/3L 突变型、单药对 照标准化疗治疗2L+ EGFR m 非鳞癌、联合K 药维持治疗1L 鳞癌）、乳腺癌4 个（联合K 药治疗术后未 达pCR 的TNBC 及1L TNBC、单药治疗2L+ HR+/HER2- BC）、子宫内膜癌2 个、2L 宫颈癌、3L+胃食 管腺癌、铂敏感复发性卵巢癌等，我们预计26Q4 开始海外陆续有数据读出。 机构：东吴证券 研究员：朱国广/张翀翯 事件：公司25 年H1 收入9.82 亿元（人民 ...

科伦博泰生物-B（06990.HK） 2025 年中报点评：业绩符合预期，核心产品 商业化进展顺利，后续管线多维度展开 买入（维持） | [Table_EPS] 盈利预测与估值 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入（百万元） | 1,540 | 1,933 | 1,943 | 3,560 | 5,894 | | 同比(%) | 91.62 | 25.48 | 0.51 | 83.22 | 65.56 | | 归母净利润（百万元） | (574.13) | (266.77) | (412.63) | (101.95) | 631.68 | | 同比(%) | 6.81 | 53.54 | (54.68) | 75.29 | 719.61 | | EPS-最新摊薄（元/股） | (2.46) | (1.14) | (1.77) | (0.44) | 2.71 | | P/E（现价&最新摊薄） | - | - | - | - | 145.74 | 证券研究报告·海外公司点评·药品 ...

Group 1: Macro Strategy and Tariff Impact - The report highlights the significant changes in the U.S. non-farm data as a reflection of the post-pandemic "K-shaped economy" differentiation, raising doubts about the effectiveness of current economic statistics [3][23] - It discusses the evolving framework of the U.S. "reciprocal tariffs" policy, which is becoming clearer with three tiers based on country agreements, affecting various industries [23][24] - The report suggests that the impact of tariffs on consumer prices in the U.S. is just beginning to manifest, with potential inflation risks remaining due to the ongoing tariff framework and domestic demand stimulation from tax cuts [25][26] Group 2: Chemical Industry - Soda Ash Investment Opportunities - The soda ash industry has about 30% of its capacity being outdated, with 10% of the capacity having energy consumption and emissions below benchmark levels [4] - The report emphasizes the importance of focusing on companies with cost advantages, particularly those using natural soda ash methods, which are more energy-efficient and cost-effective compared to synthetic methods [4] - Recommended companies include Boyuan Chemical, which is the largest domestic soda ash producer with a capacity of 6.8 million tons, and Zhongyan Chemical, which is expanding its capacity through new mining rights [4] Group 3: Pharmaceutical Industry - Kolun Biotechnology - Kolun Biotechnology's SKB264, a TROP2 ADC drug, is in the global phase III clinical trials and is considered to have blockbuster potential, with significant data expected in 2027 [5][36] - The drug has shown promising results in various indications, particularly in NSCLC, outperforming competitors in terms of progression-free survival [37][38] - The report indicates that SKB264 is positioned in the first tier of global competition, with a strong focus on its unique molecular design contributing to its efficacy and safety profile [37][38] Group 4: Electronics Industry - Lian De Equipment - Lian De Equipment has been awarded a contract for the 8.6 generation AMOLED production line, indicating its leading position in the OLED equipment market [18][27] - The company is expected to benefit from the growing demand for flexible AMOLED displays, particularly in foldable smartphones and high-end IT devices [28][29] - The report projects significant growth in the solid-state battery market, with Lian De Equipment actively developing equipment for this sector, indicating a strong future market potential [30][31] Group 5: Electronics Industry - Sunrock Electronics - Sunrock Electronics reported a sales revenue of 3.224 billion yuan in the first half of 2025, marking a year-on-year increase of 19.80% [32][33] - The company is experiencing growth in its automotive electronics and data center business, with significant contributions to its revenue from these sectors [34] - The report maintains a positive outlook on the company's profitability, projecting net profits of 1.05 billion yuan for 2025 and 1.28 billion yuan for 2026 [35]

Core Insights - The collaboration between the company and Merck focuses on the global development of TROP2 ADC, specifically the drug SKB264, which is recognized for its potential as a blockbuster product [1] - SKB264 is currently in the phase III global multi-center registration clinical trials for over ten solid tumor indications, with significant data expected to be disclosed in 2027 [1] - SKB264 has demonstrated superior efficacy in various patient populations, particularly in NSCLC, outperforming competitors in terms of median progression-free survival (mPFS) [2][3] Group 1: Product Development and Clinical Trials - SKB264 has entered the phase III clinical trial stage for multiple solid tumors, with Merck planning to disclose nine clinical trial data points in 2027 [1] - The drug has shown promising results in the first-line wild-type NSCLC population, achieving an mPFS of 15.0 months when combined with PD-1 monoclonal antibody KL-A167, surpassing other TROP2 ADCs [2] - In the PD-L1 TPS≥1% population, SKB264 achieved an mPFS of 17.8 months, and in the PD-L1 TPS<1% group, it reached 12.4 months, indicating its efficacy across different expression levels [2] Group 2: Competitive Landscape - SKB264 is positioned in the first tier of the global TROP2 ADC competition, alongside Gilead's Trodelvy and AstraZeneca/Daiichi Sankyo's Dato-DXd [1] - The molecular design of SKB264 provides it with better plasma stability and a longer half-life compared to Trodelvy, while being slightly shorter than Dato-DXd [1] Group 3: Future Directions and Market Potential - The rise of next-generation immunotherapy drugs suggests that IO+ADC combination therapies may become a key focus in the treatment of solid tumors [3] - The collaboration between BMS and BioNTech to develop a dual-specific antibody candidate highlights the commercial potential of combining IO with ADC therapies [3] Group 4: Financial Projections - The company forecasts revenues of 2.084 billion, 2.876 billion, and 4.663 billion yuan for the years 2025 to 2027, respectively, with net profits expected to improve significantly by 2027 [4]

Investment Rating - The report maintains a "Buy" rating for the company [5][7]. Core Insights - The company's core product, SKB264, is positioned as a promising ADC targeting TROP2, with significant clinical trial progress and potential for commercialization [1][14]. - SKB264 has shown superior efficacy in various clinical settings, particularly in NSCLC, outperforming competitors in terms of mPFS [2][24]. - The collaboration with Merck enhances the global development strategy for SKB264, indicating strong commercial potential [1][15]. Summary by Sections Section 1: Collaboration and Clinical Development - The company has partnered with Merck to develop SKB264, which is currently in multiple Phase III clinical trials for various indications, including NSCLC and triple-negative breast cancer [14][15]. - SKB264 is recognized as a candidate with "blockbuster potential" by Merck, reflecting confidence in its market value [16]. Section 2: Efficacy in NSCLC - In the first-line treatment of wild-type NSCLC, SKB264 demonstrated a median progression-free survival (mPFS) of 15.0 months, significantly better than other TROP2 ADCs [2][24]. - In patients with PD-L1 TPS ≥1%, the mPFS reached 17.8 months, showcasing its effectiveness in this subgroup [2][24]. - SKB264 also exhibited promising results in EGFR-mutated NSCLC patients, with a notable reduction in tumor size compared to standard treatments [3][36]. Section 3: Future Potential and Market Position - The report highlights the potential of combining next-generation immunotherapy with ADCs, positioning SKB264 as a key player in this evolving treatment landscape [4][19]. - The competitive landscape for TROP2 ADCs is intensifying, with SKB264 among the leading candidates, necessitating close monitoring of upcoming clinical data [19][21]. Section 4: Financial Projections - Revenue forecasts for the company are optimistic, with projected revenues of 2.084 billion, 2.876 billion, and 4.663 billion CNY for 2025, 2026, and 2027 respectively [5][7]. - The company is expected to achieve profitability by 2027, with a projected net profit of 561 million CNY [5].